Eli Lilly Raises 2026 Forecast After Mounjaro, Zepbound Drive Quarterly Revenue Growth
Eli Lilly (NYSE: LLY) reported first-quarter results above Wall Street estimates on Thursday and raised its full-year outlook, citing continued demand for Mounjaro and Zepbound. The company said first-quarter revenue rose 56% from a year earlier to $19.80 billion. Analysts surveyed by LSEG had expected revenue of $17.62 billion.
Adjusted earnings were $8.55 per share, compared with analyst expectations of $6.66 per share. Net income rose to $7.40 billion, or $8.26 per share, from $2.76 billion, or $3.06 per share, in the year-earlier period.
Eli Lilly now expects 2026 revenue of $82 billion to $85 billion, up from its prior forecast of $80 billion to $83 billion. The company also raised its adjusted earnings outlook to $35.50 to $37 per share, compared with its previous range of $33.50 to $35 per share.Mounjaro generated $8.66 billion in worldwide revenue during the quarter, up 125% from a year earlier. U.S. sales for the diabetes treatment were $4.2 billion. Analysts had expected global Mounjaro sales of $7.26 billion, according to StreetAccount.
Zepbound posted U.S. revenue of $4.16 billion, up 80% from the year-earlier period. Analysts had expected $4.04 billion in U.S. sales for the obesity treatment, according to StreetAccount.
U.S. revenue rose 43% to $12.1 billion, helped by a 49% increase in volume across Lilly’s products, primarily Mounjaro and Zepbound. The company said that growth was partly offset by lower realized prices for Zepbound and another medicine used for psoriatic arthritis and other conditions.
Revenue outside the U.S. increased 81% to $7.7 billion. Lilly said international growth was driven by a 95% rise in volume, partially offset by lower realized prices. Chief Executive Dave Ricks told CNBC that the company had slowed some international launches when it faced supply constraints in late 2024. He said Lilly is now several quarters into major-market launches in Europe, China and Brazil, including markets where many patients pay out of pocket.
Lilly said it held 60.1% of the U.S. obesity and diabetes drug market in the first quarter, according to an earnings presentation. Novo Nordisk’s (NYSE: NVO) share was 39.4%.
Additionally, the company’s newly approved GLP-1 pill for obesity, Foundayo, launched in the second quarter and was not included in the first-quarter results. Ricks told CNBC that more than 20,000 people had started taking Foundayo in its first few weeks on the market, with more than 1,000 new patients starting each day. Ricks also said 80% of Foundayo patients are new to GLP-1 treatments. He also said the company has not advertised the pill on television, describing current uptake as organic demand.
In February, Lilly said it expected support from Foundayo’s launch, Medicare coverage of obesity drugs later this year and continued global demand for Mounjaro and Zepbound. The company also said it expects pricing pressure from a drug pricing deal with President Donald Trump and lower cash-pay prices for Zepbound.
About Eli Lilly
Eli Lilly and Company (NYSE: LLY) is a pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company develops and markets medicines across areas including diabetes, obesity, oncology, immunology and neuroscience.
At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.